Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): A therapeutic agent for boron neutron capture therapy

Medical Physics

Volumn 26, Issue 7, 1999, Pages 1230-1236

  Zuo, Chun S ^a,b   Prasad, P V ^a   Busse, Paul ^a   Tang, L ^a   Zamenhof, R G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

BNCT; Boron; BPA; Pharmacokinetics; Proton NMR

Indexed keywords

BLOOD; BORON; CONTROLLED DRUG DELIVERY; DRUG INFUSION; NEUTRON IRRADIATION; NEUTRONS; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; SIGNAL TO NOISE RATIO; TARGETED DRUG DELIVERY; TISSUE;

BNCT; BORON NEUTRON CAPTURE THERAPY; DETECTION AND QUANTIFICATIONS; NUCLEAR MAGNETIC RESONANCE TECHNIQUES; PHYSIOLOGICAL CONCENTRATIONS; PROTON NMR; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPIC CHARACTERIZATION;

NEUTRON ACTIVATION ANALYSIS;

4 BORONOPHENYLALANINE; BORON; FLUORINE 18;

ARTICLE; DOSIMETRY; DRUG DETERMINATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; MELANOMA; NEUTRON CAPTURE THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL NOISE RATIO;

EID: 0032807987     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.598617     Document Type: Article

References (20)

1. D. E. Wazer, R. G. Zamenhof, O. K. Harling, and H. Madoc-Jones, "Boron neutron capture therapy," in Radiation Oncology: Technology and Biology, edited by P. M. Mauch and J. S. Loeffler (Saunders, Philadelphia, PA, 1994).
2. R. F. Barth, A. H. Soloway, R. G. Fairchild, and R. M. Brugger, "Boron neutron capture therapy for cancer," Cancer (N.Y.) 70, 2995-3007 (1992).
3. J. Riley and O. K. Harling, "Boron-10 analyses using prompt gamma neutron activation analysis and ICP-AES," Trans. Am. Nucl. Soc. 75, 31-32 (1996).
4. O. K. Harling, J.-M. Chabeuf, F. Lambert, and G. Yasuda, "A prompt gamma neutron activation analysis facility using a diffracted beam," Nucl. Instrum. Methods Phys. Res. B 83, 557-562 (1993).
5. P. Bendel, J. Zilberstein, and Y. Salomon, "In vivo detection of a boron-neutron-capture agent in melanoma by proton observed 1H-10B double resonance," Magn. Reson. Med. 32, 170-174 (1994).
6. P. Bendel, A. Frantz, J. Zilberstein, G. W. Kabalka, and Y. Salomon, "Boron-11 NMR of boro captate: relaxation and in vivo detection in melanoma-bearing mice," Magn. Reson. Med. 39, 439-447 (1998).
7. K. M. Bradshaw, J. R. Hadley, H. Buswell, S. P. Hendee, L. McAllister, M. P. Heilbrun, D. W. Fults III, and M. P. Schweizer, "B11 MRI studies of BSH pharmacokinetics in high-grade human brain tumors," in Advances in Neutron Capture Therapy Volume II, Chemistry and Biology, Proceedings of the Seventh International Symposium on Neutron Capture Therapy for Cancer, edited by B. Larsson, J. Crawford, and R. Weinreich (Elsevier, Zurich, Switzerland, 1996), Vol. 2, pp. 261-266.
8. P. P. Tang, M. P. Schweizer, K. M. Bradshaw, and W. F. Bauer, "11B nuclear magnetic resonance studies of the interaction of borocapture sodium with serum albumin," Biochem. Pharmacol. 49, 625-632 (1995).
9. E. B. Cady, "Quantitative combined phosphorus and proton PRESS of the brains of newborn human infants," Magn. Reson. Med. 33, 557-563 (1995).
10. J. A. Coderre, A. D. Chanana, D. D. Joel, E. H. Elowitz, P. L. Micca, M. M. Nawrocky, M. Chadha, J. O. Gebbers, M. Shady, N. S. Peress, and D. N. Slatkin, "Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: Boron concentration correlates with tumor cellularity," Radiat. Res. 149, 163-170 (1998).
11. E. H. Elowitz, R. M. Bergland, J. A. Coderre, D. D. Joel, M. Chadha, and A. D. Chanana, "Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy," Neurosurgery 42, 463-468 (1998).
12. Y. Mori, A. Suzuki, K. Yoshino, and H. Kakihana, "Complex formation of p-boronophenylalanine with some monosaccharides," Pigment Cell Res. 2, 273-277 (1989).
13. S. Mori, S. M. Eleff, U. Pilatus, N. Mori, and P. van Zijl, "Proton NMR spectroscopy of solvent-saturable resonances: A new approach to study pH effects in situ," Magn. Reson. Med. 40, 36-42 (1998).
14. J. Hu, W. Chen, G. R. Barger, and J. Evelhoch, In vivo proton MRS of human brain in the aromatic region, presented at the ISMRM, Vancouver, 1997 (unpublished).
15. R. Kreis, T. Ernst, and B. D. Ross, "Development for the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy," Magn. Reson. Med. 30, 424-437 (1993).
16. R. Kreis, J. Pietz, J. Penzien, N. Herschkowitz, and C. Boesch, Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H MRS. J. Magn. Reson., Ser. B 107, 242-251 (1995).
17. E. J. Novotny, M. Avison, N. Herschkowitz, O. Petroff, J. Prichard, M. Seashore, and D. Rothman, "In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy," Pediatr. Res. 37, 244-249 (1995).
18. J. Pietz, R. Kreis, H. Schmidt, U. Meyding-Lamade, A. Rupp, and C. Boesch, "Phenylketonuria: Findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment," Radiology 201, 413-420 (1996).
19. H. Moller, J. Weglage, D. Wiedermann, and K. Ullrich, "Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria," J. Cereb. Blood Flow Metab. 18, 1184-1191 (1998).
20. H. Moller, P. Vermathen, K. Ullrich, J. Weglage, H. Koch, and P. Peters, "In vivo NMR spectroscopy in patients with phenylketonuria: Changes of cerebral phenylalanine levels under dietary treatment," Neuropediatrics 26, 199-202 (1995).